All News

23 August 2011

Symphogen Announces Initiation of Phase 2 Trial of Sym004 EGFR Antibody Mixture in Patients with Squamous Cell Carcinoma of Head and Neck CancerAntibodies

22 August 2011

Amgen Announces PDUFA Date for XGEVA Supplemental Biologics License ApplicationAntibodies

22 August 2011

Oncobiologics, Inc. and Fox Chase Cancer Center Announce Co-Development of a Novel Cancer Therapy PlatformAntibodies

22 August 2011

PAT-SM6 Antibody Detected in Patient Tumours; Shows Intra-Tumoural ActivityAntibodies

19 August 2011

Seattle Genetics Announces FDA Accelerated Approval of ADCETRIS (Brentuximab Vedotin) for Two IndicationsAntibodies

17 August 2011

Regeneron Announces Review of Biologics License Application for EYLEA (aflibercept injection) Extended by Three Months by FDAAntibodies

17 August 2011

Emergent Announces Initiation of a Phase 1b/2 Study of TRU-016 in Combination with Rituximab and Bendamustine in Subjects with Relapsed – Indolent LymphomaAntibodies

17 August 2011

Patrys Anti-Cancer Product Shows Promise in Multiple MyelomaAntibodies

16 August 2011

4-Antibody AG Forms Collaboration with Human Genome SciencesAntibodies

10 August 2011

Boehringer Ingelheim licenses ProBioGen’s novel GlymaxX technologyAntibodies

9 August 2011

Biogen Idec and Abbott Announce Positive Top-Line Results from the First Registrational Trial for Daclizumab HYP in Relapsing-Remitting Multiple SclerosisAntibodies

8 August 2011

Genmab Announces Top-Line Phase II Results for Ofatumumab Combined with Chemotherapy in Second Line Aggressive LymphomaAntibodies

5 August 2011

Roche’s investigational treatment for asthma met its primary endpoint in a phase II studyAntibodies

5 August 2011

Roche’s RoACTEMRA approved in Europe for children living with a rare and severe form of arthritisAntibodies

1 August 2011

Femta Pharmaceuticals Announces IND Filing of FM101, a Novel Monoclonal Antibody Targeting IL-6 with Potent Anti-Inflammatory ActivityAntibodies

1 August 2011

U.S. Food and Drug Administration Approves Subcutaneous Formulation of ORENCIA (abatacept), a Proven Non-Anti-TNF Biologic for Adults with Moderate to Severe Rheumatoid ArthritisAntibodies

1 August 2011

Humabs discovers the first antibody to neutralize both group 1 and group 2 influenza A virusesAntibodies

27 July 2011

PX’Therapeutics Licenses RIBOVAX’s SEBVI Technology for the Development and Manufacturing of Fully Human Monoclonal AntibodiesAntibodies

27 July 2011

Epitomics Releases New Antibodies Developed With the National Cancer Institute’s Center for Cancer ResearchAntibodies

26 July 2011

arGEN-X Announces Non-Exclusive License With BioWa for POTELLIGENT TechnologyAntibodies

26 July 2011

CSL Limited Signs Commercial License Agreement with Selexis SAAntibodies

25 July 2011

Helix BioPharma Corp. Receives Regulatory Approval to Conduct a European Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47Antibodies

25 July 2011

Baxter Announces FDA Approval of Subcutaneous Route of Administration for GAMMAGARD LIQUID for Patients with Primary ImmunodeficiencyAntibodies

22 July 2011

FDA Advisory Committee Recommends Approval of REMICADE for Treatment of Pediatric Ulcerative ColitisAntibodies

20 July 2011

Daval International Announces Completion of Phase II Trial for the Treatment of Bladder Dysfunction With AIMSPRO in Secondary Progressive Multiple SclerosisAntibodies

15 July 2011

XGEVA (Denosumab) Granted Marketing Authorization in the European UnionAntibodies

15 July 2011

Pertuzumab Combined With Herceptin and Chemotherapy Significantly Extended the Time People With HER2-Positive Metastatic Breast Cancer Lived Without Their Disease Getting WorseAntibodies

13 July 2011

Thallion Provides Update on Phase II SHIGATEC TrialAntibodies

13 July 2011

Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid ArthritisAntibodies

12 July 2011

AnaptysBio Selects Novel Anti-IL17 mAb with Best-in-Class PotentialAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Mesothelin-Targeted Immunotherapy Pipeline Review

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

B7-H4 Targeted Antibody Therapy Pipeline Review

TL1A Inhibitor Pipeline Review

Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

EpCAM-Targeted Antibodies Pipeline Review

TROP-2-Targeted Immunotherapy Pipeline Review

FcRn Inhibitors Pipeline Review